Sign in

You're signed outSign in or to get full access.

BT

Bellerophon Therapeutics, Inc. (BLPH)·Q4 2022 Earnings Summary

Executive Summary

  • Year-end Q4 2022 update focused on clinical execution and liquidity: completed enrollment for the pivotal INOpulse REBUILD Phase 3 trial and guided to treating the last patient in Q2 2023 with top-line data expected mid-2023 . Cash and equivalents declined to $6,924K at year-end from $24,736K in 2021, reflecting higher R&D spending and ongoing trial costs .
  • Strategic positives: exclusive Greater China license signed with Baylor BioSciences ($6M license payment, 5% royalty) and NMPA IND clearance to run a Phase 3 trial for fILD in China . Capital raised via a ~$5,000K registered direct offering to support REBUILD completion and working capital .
  • Operating performance: FY 2022 net loss widened to $(19,831)K, or $(2.08) per share, driven by R&D of $16,362K as Phase 3 progressed .
  • Near-term stock reaction catalysts: pivotal mid-2023 top-line readout for REBUILD and China pathway/partnering visibility; management stated the company is “well-capitalized through top-line data” following the license and financing .

What Went Well and What Went Wrong

What Went Well

  • Completed REBUILD Phase 3 enrollment and advanced timelines: “With the INOpulse REBUILD Phase 3 study fully enrolled, we anticipate treating the last patient in the second quarter of 2023, followed by pivotal top-line data readout in mid-2023.”
  • Access to Greater China: signed exclusive license with Baylor BioSciences ($6M license payment subject to taxes/closing costs; 5% royalty on net sales across indications) and received China NMPA IND clearance to conduct a Phase 3 fILD trial using MVPA as the primary endpoint .
  • Liquidity actions to bridge to data: ~$5,000K registered direct offering to complete REBUILD and fund operations; NJ NOL/credit sale proceeds of ~$1,700K (Jan 2023) noted in context of post-year events .

What Went Wrong

  • Cash burn and lower cash balance: cash and equivalents fell to $6,924K at 12/31/22 vs $11,317K at 9/30/22 and $16,328K at 6/30/22 .
  • Losses widened year over year: FY 2022 net loss $(19,831)K vs $(17,756)K in FY 2021 and EPS $(2.08) vs $(1.87) .
  • REBUILD sample size messaging changed over time: Q3 reduced target size to 140 with >90% power and Q4 reported completion of enrollment at 145 patients; investors may question the operational rationale behind the change .

Financial Results

MetricQ2 2022Q3 2022FY 2022
Net Loss ($USD Thousands)$(4,105) $(5,069) $(19,831)
EPS ($USD)$(0.43) $(0.53) $(2.08)
Operating ExpensesQ2 2022Q3 2022FY 2022
Research and Development ($USD Thousands)$4,488 $3,750 $16,362
General and Administrative ($USD Thousands)$2,053 $1,366 $6,022
Total Operating Expenses ($USD Thousands)$6,541 $5,116 $22,384
LiquidityQ2 2022Q3 2022FY 2022
Cash and Cash Equivalents ($USD Thousands)$16,328 $11,317 $6,924

Notes:

  • The Q4 2022 press release furnished FY results rather than discrete quarterly figures; discrete Q4 net loss/EPS were not disclosed in the release .
  • No revenue line item was reported in the quarterly or annual statements furnished within the press releases .

Guidance Changes

MetricPeriodPrevious GuidanceCurrent GuidanceChange
REBUILD Enrollment Completion Timing2023Enrollment to conclude in Q1 2023 Last patient treatment in Q2 2023 Lowered/Delayed
REBUILD Top-line Data Timing2023Q3 2023 Mid-2023 Pulled forward
China fILD Trial Regulatory Status2023N/ANMPA IND cleared; Phase 3 to utilize MVPA New (positive)
Cash Runway/Capital Plan2023N/A“Well-capitalized through top-line data” post-license and ~$5,000K financing Strengthened Liquidity

Earnings Call Themes & Trends

TopicQ2 2022Q3 2022Q4 2022Trend
REBUILD Phase 3 Enrollment & Endpoint (MVPA)Enrollment continuing; plan to enroll 300; MVPA primary endpoint ~85% enrolled; target size reduced to 140; maintains >90% power for MVPA Enrollment completed at 145; last patient to be treated in Q2’23; top-line mid-2023 Accelerated completion; timeline refined
China StrategyN/AN/AIND cleared by NMPA; Greater China license signed with Baylor BioSciences New strategic pathway
PH-Sarc ProgramPoster at ATS; positive Phase 2 dose escalation top-line reiterated FDA-cleared exploratory Phase 2 chronic dosing study; next steps under assessment Assessing next steps for chronic dosing study Steady progression, planning focus
Cash/Liquidity$16,328K cash at 6/30/22 $11,317K cash at 9/30/22 $6,924K cash at 12/31/22; plus post-year $6M license payment (subject to taxes/closing), ~$5,000K raise, ~$1,700K NJ NOL sale Decline through year, bolstered post-year

Management Commentary

  • “We have achieved significant recent progress throughout our business, including advancing the INOpulse clinical program, enhancing our regulatory and commercial prospects in China, and strengthening the balance sheet.” – Peter Fernandes, CEO
  • “We anticipate treating the last patient in the second quarter of 2023, followed by pivotal top-line data readout in mid-2023.” – Peter Fernandes, CEO
  • “We continue to achieve important progress in advancing the ongoing REBUILD Phase 3 trial… We expect that enrollment will conclude in the first quarter of 2023, with the reporting of pivotal top-line data in third quarter of 2023.” – Peter Fernandes, Principal Executive Officer (Q3 release)

Q&A Highlights

  • No Q4 2022 earnings call transcript was located; the company furnished results via press releases and 8-K filings .

Estimates Context

  • Wall Street consensus for Q4 2022 EPS and revenue via S&P Global was unavailable for BLPH at this time (GetEstimates mapping not found). As a result, no beat/miss analysis vs consensus is provided.

Key Takeaways for Investors

  • The pivotal REBUILD Phase 3 top-line readout in mid-2023 is the primary near-term catalyst; management points to sufficient capital through the data following licensing and financing .
  • Strategic optionality increased with China IND clearance and Greater China licensing (upfront $6M; 5% royalty), providing a regional regulatory/commercial pathway .
  • Operating expenditures remain focused on Phase 3 completion; FY R&D of $16,362K and total opex of $22,384K drove FY net loss of $(19,831)K . Expect continued tight cost control in G&A (FY $6,022K) .
  • Cash declined to $6,924K at year-end, but subsequent non-dilutive (NJ NOL sale) and dilutive financing, plus license payment, materially enhanced liquidity into the readout .
  • Messaging on REBUILD sample size changed (140 in Q3 vs 145 enrolled by Q4), but power expectations remained strong; investors should monitor final statistical analysis plans and MVPA endpoint sensitivity .
  • Without consensus estimates, trading setups will likely center on binary clinical outcomes and capital runway; post-data, partnership and regulatory clarity may drive medium-term valuation re-rating .